Mackenzie Financial’s Heron Therapeutics HRTX Stock Holding History

Mackenzie Financial’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-58,257	Closed	-$163K	–	1477
2022 Q2	$163K	Buy	58,257 +3,975	+7%	+$16K	﹤0.01%	1303
2022 Q1	$310K	Buy	54,282 +147	+0.3%	+$1.08K	﹤0.01%	1100
2021 Q4	$494K	Buy	54,135 +23,897	+79%	+$244K	﹤0.01%	1002
2021 Q3	$323K	Sell	30,238 -228	-0.7%	-$2.78K	﹤0.01%	1103
2021 Q2	$473K	Buy	30,466 +6,040	+25%	+$96.1K	﹤0.01%	992
2021 Q1	$396K	Sell	24,426 -1,084	-4%	-$19.3K	﹤0.01%	983
2020 Q4	$540K	Buy	+25,510	New	+$443K	﹤0.01%	822
2020 Q1	–	Sell	-8,960	Closed	-$211K	–	1116
2019 Q4	$211K	Buy	+8,960	New	+$198K	﹤0.01%	1030

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Mackenzie Financial's HRTX Position: Q3 2022 in Review

Mackenzie Financial sold out of Heron Therapeutics (HRTX) in Q3 2022, closing a stake of 58,257 shares — an estimated $163K sold.

Mackenzie Financial first reported a position in HRTX in Q4 2019 and held it in 8 quarters. The position peaked at $540K in Q4 2020. 186 funds tracked by Wall St. Rank hold HRTX as of Q3 2022.

Mackenzie Financial reported no remaining Heron Therapeutics position as of Q3 2022 after selling out during the quarter.
Mackenzie Financial sold 58,257 Heron Therapeutics shares in Q3 2022, an estimated $163K.
Mackenzie Financial first reported a position in Heron Therapeutics in Q4 2019 and held it in 8 quarters.
Mackenzie Financial's Heron Therapeutics position peaked at $540K in Q4 2020.
186 funds tracked by Wall St. Rank held Heron Therapeutics as of Q3 2022.

Based on Mackenzie Financial's 13F filing for Q3 2022, filed 7 Oct 2022.